Skip to main content

Table 2 Biomarkers of cellular and plasma hypercoagulability in patients and controls

From: Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability

  Control group (n = 30) (95% CI) Breast cancer group (n = 62)
  All patients (n = 62) (95% CI) Local stage (n = 13) (95% CI) Regional stage (n = 29) (95% CI) Metastatic stage (n = 20) (95% CI)
MRI (nM/min) 109 ± 33 (96,5–121) 159 ± 47** (139–168) 172 ± 55§* (138–205) 146 ± 56§ (122–168) 162 ± 49** (126–180)
Peak (nM) 288 ± 48 (269–305) 341 ± 65* (323–365 369 ± 75** (323–414) 334 ± 90§§ (301–371) 343 ± 69§ (306–370)
ETP (nM.min) 1498 ± 225 (1413–1581) 1531 ± 337 (1448–1623) 1626 ± 332 (1424–1826) 1499 ± 374 (1366–1656) 1515 ± 285 (1369–1650)
Pd-MP (/μL) 756 ± 429 (650–1100) 10015 ± 8223§§ (7890–12138) 9370 ± 7724 (4702–14038) 7847 ± 6479*** 5334–10359) 13650 ± 9864 (8895–18404)
Pd-MP/PS + (/μL) 695 ± 361 (550–1020) 9698 ± 7931§§ (7649–11746) 9115 ± 7428 (4626–13604) 7570 ± 6241*** (5150–9991) 13231 ± 9512 (8646–17816)
PPL (sec) 72.8 ± 9.9 (59–66) 43,5 ± 10,3 (41–46) 45 ± 10,2 (39–51) 44,3 ± 9,8 (40–48) 41,3 ± 11,3$ (35–47)
D-Dimers (ng/ml) 230 ± 50 (279–340) 1250 ± 1773 (767–1648) 605 ± 499*** (303–907) 1123 ± 1429 (503–1572) 1853 ± 2497 (703–3154)
  1. Values are depicted as mean ± sd. The 95% Confidence Interval of the mean (95% CI) is also shown.
  2. *p = 0,001 versus controls, **p < 0,001 versus controls, §p < 0,01 versus controls, §§p < 0,05 versus controls, ***p < 0,05 versus metastatic stage, $p < 0,05 versus local stage.